Status
Conditions
Treatments
About
The objective of this study is the evaluation of system accuracy following ISO 15197:2013 (E), clause 6.3 in which accuracy requirements and applicable test procedures for blood glucose monitoring systems intended for self-monitoring of blood glucose by patients are stipulated. In this study, system accuracy evaluation will be performed with CE-marked BGMS (BGMS = Blood Glucose Monitoring System) common among insulin pump users - Accu-Chek Aviva Nano and Accu-Chek Performa Nano (Roche Diagnostics), FreeStyle Lite (Abbott Diabetes Care), OneTouch Verio IQ (LifeScan) Contour Next Link 2.4 (Bayer Healthcare Diabetes Care) and Accu-Chek Mobile with three different reagent system lots for each BGMS.
The study will be performed in 2 parts. Each part will comprise testing of 3 BGMS.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or female, with type 1 diabetes, type 2 diabetes or no diabetes
For provoked blood glucose excursions due to insulin dose adjustment:
Minimum age of 18 years
Signed informed consent form
Legally competent and capable to understand character, meaning and consequences of the study
Exclusion criteria
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal